These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 26303700)

  • 21. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants.
    Bousman CA; Stevenson JM; Ramsey LB; Sangkuhl K; Hicks JK; Strawn JR; Singh AB; Ruaño G; Mueller DJ; Tsermpini EE; Brown JT; Bell GC; Leeder JS; Gaedigk A; Scott SA; Klein TE; Caudle KE; Bishop JR
    Clin Pharmacol Ther; 2023 Jul; 114(1):51-68. PubMed ID: 37032427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treating agitation and aggression in patients with Alzheimer's disease with escitalopram.
    Žmuc Veranič L; Pregelj P; Jerin A
    Psychogeriatrics; 2016 Nov; 16(6):384-385. PubMed ID: 26551073
    [No Abstract]   [Full Text] [Related]  

  • 23. Treating dementia and agitation.
    Small GW
    JAMA; 2014 Feb; 311(7):677-8. PubMed ID: 24549545
    [No Abstract]   [Full Text] [Related]  

  • 24. Serotonergic Regulation and Cognition after Stroke: The Role of Antidepressant Treatment and Genetic Variation.
    Damsbo AG; Kraglund KL; Buttenschøn HN; Johnsen SP; Andersen G; Mortensen JK
    Cerebrovasc Dis; 2019; 47(1-2):72-79. PubMed ID: 30844812
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Citalopram decreases agitation in the context of Alzheimer's disease, but at doses higher than those commonly prescribed and at the expense of side effects.
    Underwood BR; Fox C
    Evid Based Med; 2014 Oct; 19(5):181. PubMed ID: 24824622
    [No Abstract]   [Full Text] [Related]  

  • 26. Randomized Placebo-Controlled Trial of Nabilone for Agitation in Alzheimer's Disease.
    Herrmann N; Ruthirakuhan M; Gallagher D; Verhoeff NPLG; Kiss A; Black SE; Lanctôt KL
    Am J Geriatr Psychiatry; 2019 Nov; 27(11):1161-1173. PubMed ID: 31182351
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacogenetic Factors Influence Escitalopram Pharmacokinetics and Adverse Events in Youth with a Family History of Bipolar Disorder: A Preliminary Study.
    Honeycutt DC; Blom TJ; Ramsey LB; Strawn JR; Bruns KM; Welge JA; Patino LR; Singh MK; DelBello MP
    J Child Adolesc Psychopharmacol; 2024 Feb; 34(1):42-51. PubMed ID: 38377518
    [No Abstract]   [Full Text] [Related]  

  • 28. A pilot open-label trial of citalopram for restless activity and aberrant motor behaviors in Alzheimer disease.
    Scharre DW; Davis RA; Warner JL; Chang SI; Beversdorf DQ
    Am J Geriatr Psychiatry; 2003; 11(6):687-91. PubMed ID: 14609811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer's Dementia: Evidence From the CitAD Study.
    Leonpacher AK; Peters ME; Drye LT; Makino KM; Newell JA; Devanand DP; Frangakis C; Munro CA; Mintzer JE; Pollock BG; Rosenberg PB; Schneider LS; Shade DM; Weintraub D; Yesavage J; Lyketsos CG; Porsteinsson AP;
    Am J Psychiatry; 2016 May; 173(5):473-80. PubMed ID: 27032628
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Can antidepressant medication relieve agitation in Alzheimer's disease?
    Porsteinsson AP; Smith JS; Keltz MA; Antonsdottir IM
    Expert Rev Neurother; 2014 Sep; 14(9):969-71. PubMed ID: 25148535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial.
    Cummings JL; Lyketsos CG; Peskind ER; Porsteinsson AP; Mintzer JE; Scharre DW; De La Gandara JE; Agronin M; Davis CS; Nguyen U; Shin P; Tariot PN; Siffert J
    JAMA; 2015 Sep 22-29; 314(12):1242-54. PubMed ID: 26393847
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses.
    Mintzer JE; Tune LE; Breder CD; Swanink R; Marcus RN; McQuade RD; Forbes A
    Am J Geriatr Psychiatry; 2007 Nov; 15(11):918-31. PubMed ID: 17974864
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacogenetics of citalopram-related side effects in children with depression and/or anxiety disorders.
    Amitai M; Kronenberg S; Carmel M; Michaelovsky E; Frisch A; Brent D; Apter A; Chen A; Weizman A; Fennig S
    J Neural Transm (Vienna); 2016 Nov; 123(11):1347-1354. PubMed ID: 27324805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association between serotonin 2A receptor (HTR2A), serotonin transporter (SLC6A4) and brain-derived neurotrophic factor (BDNF) gene polymorphisms and citalopram/sertraline induced sexual dysfunction in MDD patients.
    Oz MD; Baskak B; Uckun Z; Artun NY; Ozdemir H; Ozel TK; Ozguven HD; Suzen HS
    Pharmacogenomics J; 2020 Jun; 20(3):443-450. PubMed ID: 31792367
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial.
    Fox C; Crugel M; Maidment I; Auestad BH; Coulton S; Treloar A; Ballard C; Boustani M; Katona C; Livingston G
    PLoS One; 2012; 7(5):e35185. PubMed ID: 22567095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advancements in the treatment of agitation in Alzheimer's disease.
    Antonsdottir IM; Smith J; Keltz M; Porsteinsson AP
    Expert Opin Pharmacother; 2015; 16(11):1649-56. PubMed ID: 26159445
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Citalopram for verbal agitation in patients with dementia.
    Kim KY; Bader GM; Jones E
    J Geriatr Psychiatry Neurol; 2000; 13(2):53-5. PubMed ID: 10912724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multicenter, randomized, placebo-controlled, double-blind clinical trial of escitalopram on the progression-delaying effects in Alzheimer's disease.
    Choe YM; Kim KW; Jhoo JH; Ryu SH; Seo EH; Sohn BK; Byun MS; Bak JH; Lee JM; Yun HJ; Han MI; Woo JI; Lee DY
    Int J Geriatr Psychiatry; 2016 Jul; 31(7):731-9. PubMed ID: 26553313
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: a randomized, controlled trial.
    Tariot PN; Raman R; Jakimovich L; Schneider L; Porsteinsson A; Thomas R; Mintzer J; Brenner R; Schafer K; Thal L; ;
    Am J Geriatr Psychiatry; 2005 Nov; 13(11):942-9. PubMed ID: 16286437
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Longitudinal Course of Agitation and Aggression in Patients with Alzheimer's Disease in a Cohort Study: Methods, Baseline and Longitudinal Results of the A3C Study.
    De Mauleon A; Delrieu J; Cantet C; Vellas B; Andrieu S; Rosenberg PB; Lyketsos CG; Soto Martin M
    J Prev Alzheimers Dis; 2021; 8(2):199-209. PubMed ID: 33569568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.